129 related articles for article (PubMed ID: 38858079)
41. Marmosets as model systems for the study of Alzheimer's disease and related dementias: substantiation of physiological Tau 3R and 4R isoform expression and phosphorylation.
Huhe H; Shapley SM; Duong D; Wu F; Ha SK; Choi SH; Kofler J; Mou Y; Guimaraes TR; Thathiah A; Schaeffer LKH; Carter GW; Seyfried NT; Silva AC; Sukoff Rizzo SJ
bioRxiv; 2024 Apr; ():. PubMed ID: 38746277
[TBL] [Abstract][Full Text] [Related]
42. SMaRT modulation of tau isoforms rescues cognitive and motor impairments in a preclinical model of tauopathy.
Muñiz JA; Facal CL; Urrutia L; Clerici-Delville R; Damianich A; Ferrario JE; Falasco G; Avale ME
Front Bioeng Biotechnol; 2022; 10():951384. PubMed ID: 36277399
[TBL] [Abstract][Full Text] [Related]
43. Frontotemporal dementia with novel tau pathology and a Glu342Val tau mutation.
Lippa CF; Zhukareva V; Kawarai T; Uryu K; Shafiq M; Nee LE; Grafman J; Liang Y; St George-Hyslop PH; Trojanowski JQ; Lee VM
Ann Neurol; 2000 Dec; 48(6):850-8. PubMed ID: 11117541
[TBL] [Abstract][Full Text] [Related]
44. Tau isoform expression in frontotemporal dementia without tau deposition.
Sutherland GT; Nowak G; Halliday GM; Kril JJ
J Clin Neurosci; 2007 Dec; 14(12):1182-5. PubMed ID: 17976991
[TBL] [Abstract][Full Text] [Related]
45. Three repeat isoforms of tau inhibit assembly of four repeat tau filaments.
Adams SJ; DeTure MA; McBride M; Dickson DW; Petrucelli L
PLoS One; 2010 May; 5(5):e10810. PubMed ID: 20520830
[TBL] [Abstract][Full Text] [Related]
46. Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies.
Rockenstein E; Ubhi K; Mante M; Florio J; Adame A; Winter S; Brandstaetter H; Meier D; Masliah E
BMC Neurosci; 2015 Nov; 16():85. PubMed ID: 26611895
[TBL] [Abstract][Full Text] [Related]
47. Pathological tau phenotypes. The weight of mutations, polymorphisms, and differential neuronal vulnerabilities.
Mailliot C; Bussière T; Hamdane M; Sergeant N; Caillet ML; Delacourte A; Buée L
Ann N Y Acad Sci; 2000; 920():107-14. PubMed ID: 11193138
[TBL] [Abstract][Full Text] [Related]
48. [Frontotemporal dementia: tau mutations, deposition, and molecular mechanisms of neuronal cell death].
Hasegawa M
Rinsho Shinkeigaku; 2004 Nov; 44(11):879-81. PubMed ID: 15651320
[TBL] [Abstract][Full Text] [Related]
49. The neuropathology of frontotemporal lobar degeneration with respect to the cytological and biochemical characteristics of tau protein.
Taniguchi S; McDonagh AM; Pickering-Brown SM; Umeda Y; Iwatsubo T; Hasegawa M; Mann DM
Neuropathol Appl Neurobiol; 2004 Feb; 30(1):1-18. PubMed ID: 14720172
[TBL] [Abstract][Full Text] [Related]
50. GSK-3beta phosphorylation of functionally distinct tau isoforms has differential, but mild effects.
Voss K; Gamblin TC
Mol Neurodegener; 2009 May; 4():18. PubMed ID: 19409104
[TBL] [Abstract][Full Text] [Related]
51. From genotype to phenotype: a clinical pathological, and biochemical investigation of frontotemporal dementia and parkinsonism (FTDP-17) caused by the P301L tau mutation.
Nasreddine ZS; Loginov M; Clark LN; Lamarche J; Miller BL; Lamontagne A; Zhukareva V; Lee VM; Wilhelmsen KC; Geschwind DH
Ann Neurol; 1999 Jun; 45(6):704-15. PubMed ID: 10360762
[TBL] [Abstract][Full Text] [Related]
52. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands.
Rizzu P; Van Swieten JC; Joosse M; Hasegawa M; Stevens M; Tibben A; Niermeijer MF; Hillebrand M; Ravid R; Oostra BA; Goedert M; van Duijn CM; Heutink P
Am J Hum Genet; 1999 Feb; 64(2):414-21. PubMed ID: 9973279
[TBL] [Abstract][Full Text] [Related]
53. Developmental regulation of alternatively spliced isoforms of mRNA encoding MAP2 and tau in rat brain oligodendrocytes during culture maturation.
Richter-Landsberg C; Gorath M
J Neurosci Res; 1999 May; 56(3):259-70. PubMed ID: 10336255
[TBL] [Abstract][Full Text] [Related]
54. Differential incorporation of tau isoforms in Alzheimer's disease.
Espinoza M; de Silva R; Dickson DW; Davies P
J Alzheimers Dis; 2008 May; 14(1):1-16. PubMed ID: 18525123
[TBL] [Abstract][Full Text] [Related]
55. Blocking Site-Specific Cleavage of Human Tau Delays Progression of Disease-Related Phenotypes in Genetically Matched Tau-Transgenic Mice Modeling Frontotemporal Dementia.
Steuer EL; Kemper LJ; Hlynialuk CJW; Leinonen-Wright K; Montonye ML; Lapcinski IP; Forster CL; Ashe KH; Liu P
J Neurosci; 2022 Jun; 42(23):4737-4754. PubMed ID: 35508385
[TBL] [Abstract][Full Text] [Related]
56. Regulation of tau isoform expression and dementia.
D'Souza I; Schellenberg GD
Biochim Biophys Acta; 2005 Jan; 1739(2-3):104-15. PubMed ID: 15615630
[TBL] [Abstract][Full Text] [Related]
57. Microtubule associated protein (tau) gene variability in patients with frontotemporal dementia.
Kowalska A; Takahashi K; Kozubski W; Tabira T
Folia Neuropathol; 2002; 40(1):1-5. PubMed ID: 12121033
[TBL] [Abstract][Full Text] [Related]
58. Novel marker for the onset of frontotemporal dementia: early increase in activity-dependent neuroprotective protein (ADNP) in the face of Tau mutation.
Schirer Y; Malishkevich A; Ophir Y; Lewis J; Giladi E; Gozes I
PLoS One; 2014; 9(1):e87383. PubMed ID: 24489906
[TBL] [Abstract][Full Text] [Related]
59. Increased expression of three-repeat isoforms of tau contributes to tau pathology in a rat model of chronic type 2 diabetes.
Jung HJ; Park SS; Mok JO; Lee TK; Park CS; Park SA
Exp Neurol; 2011 Apr; 228(2):232-41. PubMed ID: 21281635
[TBL] [Abstract][Full Text] [Related]
60. [Aberrant Interaction Between FUS and SFPQ in Neurons in a Wide Range of FTLD Spectrum Diseases].
Ishigaki S
Brain Nerve; 2021 Sep; 73(9):1021-1028. PubMed ID: 34462374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
